The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
Open accessPublished version of a preprint
Abstract
Immune protection following either vaccination or infection with SARS-CoV-2 is thought to decrease over time. We designed a retrospective study, conducted at Leumit Health Services in Israel, to determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals. Antibody titers were measured between 31 January 2021, and 31 July 2021 in two mutually exclusive groups: (i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and (ii) SARS-CoV-2 convalescents who had not received the vaccine. A total of 2653 individuals fully vaccinated by two doses of vaccine during the study period and 4361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8–5644.6]) after the second vaccination than in convalescent individuals (median 355.3 AU/mL IQR [141.2–998.7]; p < 0.001). In vaccinated subjects, antibody titers decreased by up to 38% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection. This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Perineuronal nets stabilize the grid cell network
Christensen, A. C., Lensjø, K. K., Lepperød, M. E., Dragly, S.-A., Sutterud, H., Blackstad, J. S., Fyhn, M., & Hafting, T. (2021) · Nature Communications · doi:10.1038/s41467-020-20241-w · Cited by 1,865
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137 · cited 1×
“One limitation of our data is that the assay used in our study does not specially measure neutralizing antibodies; nevertheless, a high correlation was observed between a surrogate virus neutralization assay and other assays such as the Roche Elecsys anti-S pan-Ig assay [21,43].”
MethodCorrelates of Protection Against SARS-CoV-2 in Rhesus Macaques
McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021) · Nature · doi:10.1038/s41586-020-03041-6 · Cited by 1,068
Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19
Ibarrondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A., Ferbas, K. G., Tobin, N. H., Aldrovandi, G. M., & Yang, O. O. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2025179 · Cited by 1,021
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
Research works printed but not linked: 24
- Khoury, 2021, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat. Med., 27, 1205, 10.1038/s41591-021-01377-8 · DOI · Paper page
- Kim, 2021, Looking beyond COVID-19 vaccine phase 3 trials, Nat. Med., 27, 205, 10.1038/s41591-021-01230-y · DOI · Paper page
- Wheatley, 2021, Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19, Nat. Commun., 12, 1162, 10.1038/s41467-021-21444-5 · DOI · Paper page
- Raz, 2021, One size does not fit all: Lessons from Israel’s COVID-19 vaccination drive and hesitancy, Vaccine, 39, 4027, 10.1016/j.vaccine.2021.06.004 · DOI
- Sampieri, 2021, SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants, Front. Immunol., 12, 701501, 10.3389/fimmu.2021.701501 · DOI · Paper page
- Muhsen, 2021, A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020–February 2021, Lancet Reg. Health Eur., 7, 100130, 10.1016/j.lanepe.2021.100130 · DOI
- Rennert, 2001, Prevalence of selected chronic diseases in Israel, Isr. Med. Assoc. J., 3, 404
- Hamood, 2016, A feasibility study to assess the validity of administrative data sources and self-reported information of breast cancer survivors, Isr. J. Health Policy Res., 5, 50, 10.1186/s13584-016-0111-6 · DOI
- Grupel, 2021, Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination, Vaccine, 39, 5337, 10.1016/j.vaccine.2021.08.025 · DOI
- Turner, 2021, SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses, Nature, 596, 109, 10.1038/s41586-021-03738-2 · DOI · Paper page
- Breuer, 2021, SARS-CoV-2 antibodies started to decline just four months after COVID-19 infection in a paediatric population, Acta Paediatr., 110, 3054, 10.1111/apa.16031 · DOI
- Meyer, 2021, Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: A prospective longitudinal study, Clin. Microbiol. Infect., 27, 784.e1, 10.1016/j.cmi.2021.01.005 · DOI
- Cho, 2021, Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination, Nature, 600, 517, 10.1038/s41586-021-04060-7 · DOI · Paper page
- Ebinger, 2021, Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2, Nat. Med., 27, 981, 10.1038/s41591-021-01325-6 · DOI · Paper page
- Padoan, 2021, Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers, Clin. Chim. Acta, 519, 60, 10.1016/j.cca.2021.04.006 · DOI
- Cupaiolo, 2021, Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers, J. Infect., 83, 237
- Grobecker, 2021, SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19, Infection, 49, 739, 10.1007/s15010-021-01598-6 · DOI
- Schoof, 2020, An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike, Science, 370, 1473, 10.1126/science.abe3255 · DOI · Paper page
- Pedotti, 2021, Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice, Nature, 593, 424, 10.1038/s41586-021-03461-y · DOI
- Xu, 2021, Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants, Nature, 595, 278, 10.1038/s41586-021-03676-z · DOI · Paper page
- Iwasaki, 2016, Exploiting Mucosal Immunity for Antiviral Vaccines, Annu. Rev. Immunol., 34, 575, 10.1146/annurev-immunol-032414-112315 · DOI
- Li, 2021, In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies, Cell, 184, 4203, 10.1016/j.cell.2021.06.021 · DOI · Paper page
- Iyer, 2020, Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients, Sci. Immunol., 5, 367, 10.1126/sciimmunol.abe0367 · DOI · Paper page
- Hellerstein, 2020, What are the roles of antibodies versus a durable, high-quality T-cell response in protective immunity against SARS-CoV-2?, Vaccine, 6, 100076
Cited by
Röltgen, K., Nielsen, S. C. A., Silva, O., Younes, S. F., Zaslavsky, M., Costales, C., Yang, F., Wirz, O. F., Solis, D., Hoh, R. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.018 · Cited by 469
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 269
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
Israel, A., Merzon, E., Schäffer, A. A., Shenhar, Y., Green, I., Golan-Cohen, A., Ruppin, E., Magen, E., & Vinker, S. (2021) · BMJ · doi:10.1136/bmj-2021-067873 · Cited by 170
Self-citation
Metadata
- Authors
- Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan-Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2021-12-31
- Volume
- 10
- Issue
- 1
- Pages
- 64
- ISSN
- 2076-393X (ISSN-L)
- OpenAlex
- W4225489846
- Cited by
- 218
- References
- 17
- FWCI
- 14.66
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- National Cancer Institute (Intramural Research program)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. https://app.cochat.ai/papers/10.3390/vaccines10010064
- The paper
- Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan-Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E. (2021). Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. Vaccines. https://doi.org/10.3390/vaccines10010064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.